Result of AGM

Summary by AI ^BETAClose X

Arecor Therapeutics plc announced that all resolutions were passed at its Annual General Meeting, with the exception of Resolution 5 concerning the re-election of Andrew Richards, which saw 31.82% of votes cast against it. The company will engage with shareholders to understand concerns regarding this resolution. Other resolutions, including the approval of the directors' remuneration report and policy, re-election of other directors, auditor re-appointment, and share allotment authorities, received strong support, with most resolutions passing with over 95% of votes in favour.

Disclaimer*

Arecor Therapeutics PLC

28 May 2026

Arecor Therapeutics plc
("Arecor" or the "Company")

Result of AGM

Cambridge, UK, 28 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces that at its Annual General Meeting held earlier today, all resolutions were passed.

The full text of each resolution was included in the Company's Notice of Annual General Meeting made available on the Company's website.

The number of proxy votes cast for and against each of the resolutions proposed, and the number of proxy votes withheld are shown in the table below.

The Board notes that 31.82% of votes were against Resolution 5. The Board confirms that it will consult and continue to engage with shareholders to understand and discuss their concerns with respect to this resolution.

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 To receive the directors' report, the consolidated financial statements and the auditors' report for the year ended 31 December 2025	17,588,351	100%	0	0%	0
Resolution 2 To approve the directors' remuneration report as set out on pages 31 to 36 in the annual report for the year ended 31 December 2025	16,756,524	95.30%	827,227	4.70%	4,600
Resolution 3 To approve the director's remuneration policy as set out on pages 32 to 34 in the annual report for the year ended 31 December 2025	16,756,524	95.30%	827,227	4.70%	4,600
Resolution 4 To re-elect Sarah Howell as a Director of the Company in accordance with the articles	16,756,524	100.00%	0	0.00%	831,827
Resolution 5 To re-elect Andrew Richards as a Director of the company in accordance with the articles	11,952,304	68.18%	5,576,941	31.82%	59,106
Resolution 6 To re-elect Sam Fazeli as a Director of the Company in accordance with the articles	16,756,524	100.00%	0	0.00%	831,827
Resolution 7 To re-elect Jeremy Morgan as a Director of the Company in accordance with the articles	16,756,524	95.30%	827,227	4.70%	4,600
Resolution 8 To re-elect Simon Ormiston as a Director of the Company in accordance with the articles	16,756,524	100.00%	0	0.00%	831,827
Resolution 9 To re-elect David Ellam as a Director of the Company in accordance with the articles	16,756,524	100.00%	0	0.00%	831,827
Resolution 10 To re-appoint PKF Littlejohn LLP as auditors of the Company	17,575,001	99.93%	11,500	0.07%	1,850
Resolution 11 To authorise the Directors to agree the auditors' remuneration	17,588,351	100.00%	0	0.00%	0
Resolution 12 To authorise the allotment of shares	17,459,642	99.59%	71,453	0.41%	0
Resolution 13 To disapply statutory pre-emption rights	17,503,110	99.53%	83,391	0.47%	1,850

-ENDS-

For more information, please contact:

Arecor Therapeutics plc
Dr Sarah Howell, Chief Executive Officer
David Ellam, Chief Financial Officer

+44 (0) 1223 426060

info@arecor.com

Singer Capital Markets Advisory LLP
(NOMAD and Broker)
Phil Davies, James Fischer

+44 (0) 20 7496 3000

Vigo Consulting (Financial Communications)
Melanie Toyne-Sewell, Rozi Morris

+44 (0) 20 7390 0230

arecor@vigoconsulting.com

Vida Strategic Partners (US Investor Relations)

Stephanie Diaz

+1 (415) 675-7401

sdiaz@vidasp.com

Notes to Editors

About Arecor

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel's twiist™ AID system. Clinically de-risked, AT278 is designed to transform AID systems, addressing a multi-billion dollar diabetes market. Arecor is also developing a novel oral delivery platform for peptides with GLP-1 receptor agonists its first validation target.

The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.

Arecor® and Arestat® are registered trademarks of Arecor Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END